Noxopharm
(ASX:NOX) CEO Dr. Graham Kelly and Ian Minns Director Clinical Development and Medical Affairs provide an update on clinical trials, including applications for both common and rare cancers.
When Noxopharm started 9 months ago it was an Oncology company with a single product in NOX-66 which has now expanded to 3 products thanks to a valuable technology platform that have been developed. The platform has enabled the company to expand outside oncology so in all there are now 5 clinical programs running.
The presentation today will cover 3 of the programs starting with NOX-66.
